Zachary Hunter
Pre-Doctoral Trainee
Boston University School of Medicine, Division of Graduate Medical Sciences
Dept of Pathology & Laboratory Medicine




Waldenström's macroglobulinemia
Whole Genome Sequencing
Lymphoma Predisposition
Bioinformatics
Genetics
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Castillo JJ, Gustine JN, Meid K, Dubeau TE, Xu L, Yang G, Hunter ZR, Advani R, Palomba L, Treon SP. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia. Haematologica. 2018 May 17. PMID: 29773590.
     
  2. Castillo JJ, Dubeau T, Kofides A, Demos MG, Tsakmaklis N, Xu L, Hunter ZR, Treon SP. Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström Macroglobulinemia. Am J Hematol. 2018 May 14. PMID: 29756293.
     
  3. Castillo JJ, Meid K, Gustine JN, Dubeau T, Severns P, Hunter ZR, Yang G, Xu L, Treon SP. Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia. Clin Cancer Res. 2018 Apr 16. PMID: 29661775.
     
  4. Guerrera ML, Tsakmaklis N, Xu L, Yang G, Demos M, Kofides A, Chan GG, Manning RJ, Liu X, Chen JG, Munshi M, Patterson CJ, Castillo JJ, Dubeau T, Gustine J, Carrasco RD, Arcaini L, Varettoni M, Cazzola M, Treon SP, Hunter ZR. MYD88 mutated and wild-type Waldenströms Macroglobulinemia: Characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4. Haematologica. 2018 Mar 29. PMID: 29599202.
     
  5. Castillo JJ, Gustine JN, Meid K, Dubeau T, Severns P, Xu L, Yang G, Hunter ZR, Treon SP. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia. Br J Haematol. 2018 Mar 13. PMID: 29532913.
     
  6. Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Chan GG, Patterson CJ, Meid K, Gustine J, Dubeau T, Severns P, Castillo JJ, Hunter ZR, Wang J, Buhrlage SJ, Gray NS, Treon SP, Yang G. BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. Blood. 2018 May 03; 131(18):2047-2059. PMID: 29496671.
     
  7. Castillo JJ, Gustine JN, Meid K, Dubeau TE, Severns P, Xu L, Yang G, Hunter ZR, Treon SP. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. Br J Haematol. 2018 Apr; 181(1):77-85. PMID: 29468652.
     
  8. Gustine JN, Meid K, Dubeau T, Severns P, Hunter ZR, Guang Y, Xu L, Treon SP, Castillo JJ. Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound. Am J Hematol. 2018 Aug; 93(4):511-517. PMID: 29280186.
     
  9. Mancek-Keber M, Lainšcek D, Bencina M, Chen JG, Romih R, Hunter ZR, Treon SP, Jerala R. Extracellular vesicle-mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling. Blood. 2018 Apr 12; 131(15):1720-1729. PMID: 29358175.
     
  10. Castillo JJ, Gustine JN, Meid K, Xu L, Hunter ZR, Treon SP. Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia. Am J Hematol. 2018 Mar; 93(3):E69-E71. PMID: 29218718.
     
Showing 10 of 104 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 104 publications over 14 distinct years, with a maximum of 13 publications in 2016

YearPublications
20045
20053
20066
20076
200811
20096
201112
20123
20135
201410
20158
201613
20177
20189
Contact for Mentoring:


Hunter's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Similar People
_
Same Department